Table 1.
Selected Baseline Characteristics of 1178 Participants Categorized by Vital Status at the End of Follow-Up
| Characteristic | Alive (n=891) | Deceased (n=287) | P Value |
|---|---|---|---|
| Age, y | 70.3±6.1 | 73.1±6.9 | <0.001 |
| Female, % | 63.3 | 47.4 | <0.001 |
| Race/ethnicity, % | 0.003 | ||
| White | 45.6 | 55.4 | |
| Hispanic | 41.0 | 30.0 | |
| Black | 13.4 | 14.6 | |
| Randomization to telemedicine, % | 50.3 | 49.1 | 0.74 |
| CHF, % | 9.5 | 25.4 | <0.001 |
| Previous myocardial infarction, % | 14.6 | 31.7 | <0.001 |
| Previous stroke, % | 8.6 | 14.6 | 0.003 |
| Duration of diabetes mellitus, y | 10.4±8.9 | 13.2±10 | <0.001 |
| Currently smoking, % | 7.1 | 11.5 | 0.014 |
| Taking ACE-I/ARB, % | 63.0 | 59.6 | 0.17 |
| Taking β-blocker, % | 25.7 | 29.8 | 0.10 |
| Taking calcium channel blocker, % | 29.1 | 28.2 | 0.82 |
| Taking diuretic, % | 25.6 | 22.3 | 0.27 |
| Taking any antihypertensive medication, % | 81.1 | 81.1 | 0.98 |
| Body mass index, kg/m2 | 31.4±6.2 | 30.6±6.3 | 0.06 |
| Albumin:creatinine ratio, mg/g | 15.6 (8.1 to 40.9) | 54.9 (15.7 to 224.4) | <0.001 |
| Hemoglobin A1c | 7.4±1.4 | 7.5±1.7 | 0.07 |
| HDL cholesterol, mg/dL | 47.8±13.2 | 43.4±14.9 | <0.001 |
| LDL cholesterol, mg/dL | 106.6±33.4 | 107.7±40.6 | 0.83 |
| Triglycerides, mg/dL | 165.9±93.4 | 182.6±118.4 | 0.015 |
| Office systolic BP, mm Hg | 140.7±22.2 | 143.5±24.7 | 0.07 |
| Office diastolic BP, mm Hg | 70.8±10.7 | 70.7±10.7 | 0.91 |
| Office PP, mm Hg | 69.9±17.7 | 72.8±10.7 | 0.019 |
| Office HR, bpm | 69.7±10.8 | 72.8±10.9 | <0.001 |
| 24-hour systolic BP, mm Hg | 132.5±13.9 | 136.4±16.9 | <0.001 |
| 24-hour diastolic BP, mm Hg | 69.2±8.2 | 69.2±8.9 | 0.97 |
| 24-hour PP, mm Hg | 63.3±13.2 | 67.2±13.7 | <0.001 |
| Sleep blood pressure pattern, %* | 0.006 | ||
| Dipping | 32.4 | 23.3 | |
| Nondipping | 48.8 | 51.6 | |
| Rise | 18.8 | 25.1 | |
| Sleep heart rate pattern, %* | <0.001 | ||
| Dipping | 50.5 | 34.5 | |
| Nondipping | 39.6 | 47.4 | |
| Rise | 9.9 | 18.1 | |
| AASI (×10) | 5.1±1.4 | 5.5±1.5 | <0.001 |
Data are from the IDEATel Study, New York, 2000–2008. Data are means±SDs, median (interquartile range), or percentages. ACE inhibitors indicates angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers. Comparisons were made, as appropriate, using the χ2 or Fisher’s exact tests for categorical variables and Student t or Mann–Whitney U test for continuous variables. AASI has no units.
*
P for linear trend.